Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.20

Astria Therapeutics, Inc. (NASDAQ:ATXS) has earned an average rating of “Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $25.20.

Several research firms have recently weighed in on ATXS. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Oppenheimer upped their target price on Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, TD Cowen assumed coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 target price on the stock.

Institutional Trading of Astria Therapeutics

Several hedge funds have recently modified their holdings of the company. Nantahala Capital Management LLC acquired a new stake in shares of Astria Therapeutics in the 2nd quarter worth $6,142,000. Susquehanna Fundamental Investments LLC acquired a new stake in Astria Therapeutics in the 2nd quarter worth approximately $400,000. Millennium Management LLC grew its position in Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after purchasing an additional 218,518 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in Astria Therapeutics by 15.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock valued at $8,878,000 after purchasing an additional 130,000 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Astria Therapeutics in the second quarter worth $2,561,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Stock Down 0.1 %

Shares of Astria Therapeutics stock opened at $10.62 on Tuesday. The stock’s fifty day moving average is $11.15 and its two-hundred day moving average is $11.07. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90. The company has a market capitalization of $583.18 million, a PE ratio of -4.58 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, research analysts anticipate that Astria Therapeutics will post -1.66 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.